 |
MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
Feb 28, 2008
|
14.7 KB |
|
| |
MOUNTAIN VIEW, Calif., Feb 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2007.
The net loss for the fourth quarter and year ended December 31, 2007 was $14.9 million and $40.1 million, respectively, compared...
|
|
MAP Pharmaceuticals Announces Resignation of Chief Medical Officer
Feb 5, 2008
|
7.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Feb 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, announced today that Stephen B. Shrewsbury, M.B., Ch.B., Chief Medical Officer, will be leaving the company for personal reasons in early March 2008. Dr. Shrewsbury plans to provide cons...
|
|
MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Jan 30, 2008
|
7.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Wednesday, February 6, 2008, at 1:40 pm (ET) in New York City.
A live webcast of t...
|
|
MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
Jan 16, 2008
|
11.2 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, today announced that it has completed the special protocol assessment (SPA) process with the U.S. Food and Drug Administration (FDA) for the first Phase 3 clinical trial of its MAP0004 p...
|
|
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial of Unit Dose Budesonide in Children with Asthma
Jan 7, 2008
|
10.4 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, today announced it has initiated a Phase 3 clinical trial evaluating Unit Dose Budesonide (UDB), the company's proprietary nebulized version of budesonide, for the potential treatment of...
|
|
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 27, 2007
|
7.2 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 27, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the following upcoming investor conferences on November 28th and December 12th, 2007 in New York City:
Lazard Capital Markets Fourth Annual Healthcare Conference
...
|
|
MAP Pharmaceuticals Reports Third Quarter Financial Results
Nov 7, 2007
|
11.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, today announced financial results for the third quarter ended September 30, 2007.
The net loss attributable to common stockholders for the third quarter of 2007 was $11.7 million com...
|
|
MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
Oct 31, 2007
|
11.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, today announced the initiation of a Phase 2a clinical trial evaluating MAP0005 for the potential treatment of asthma and chronic obstructive pulmonary disease (COPD).
MAP0005 is a co...
|
|
MAP Pharmaceuticals Announces Exercise of Over-Allotment Option of 750,000 Shares of Common Stock
Oct 9, 2007
|
7.5 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct 09, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that the underwriters of its public offering of 5,000,000 shares of common stock have exercised their over-allotment option in full to purchase an additional 750,000 shares of common stock at the initial pub...
|
|
MAP Pharmaceuticals Announces Pricing of its Initial Public Offering
Oct 5, 2007
|
6.9 KB |
|
| |
Mountain View, CA, October 5, 2007 - MAP Pharmaceuticals, Inc. announced today that it has priced its initial public offering of 5,000,000 shares of common stock at a price of $12.00 per share. All shares are being offered by MAP Pharmaceuticals. In addition, MAP Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an...
|
|
MAP Pharmaceuticals Appoints Shashidhar Kori New Vice President of Clinical Development
Aug 10, 2007
|
8.8 KB |
|
| |
Mountain View, CA, August 10, 2007 -- MAP Pharmaceuticals, Inc.
today announced the appointment of Dr. Shashidhar Kori, M.D. to
the position of Vice President of Clinical Development.
Dr. Kori has spent over 30 years in drug development and academic
research in the field of neur...
|
|
MAP Pharmaceuticals Promotes Stephen B. Shrewsbury to Position of Chief Medical Officer
Aug 10, 2007
|
6.4 KB |
|
| |
Mountain View, CA, August 10, 2007 -- MAP Pharmaceuticals, Inc.
today announced that Stephen B. Shrewsbury, M.B. Ch.B., has been
promoted to Chief Medical Officer, a newly created position. Dr.
Shrewsbury most recently served as the company's Vice President,
Clinical and Regulatory Af...
|
|
MAP Pharmaceuticals Appoints Charlene A. Friedman General Counsel
Jul 26, 2007
|
4.8 KB |
|
| |
Mountain View, CA, July 26, 2007 /PRNewswire/ -- MAP Pharmaceuticals,
Inc. today announced the appointment of Charlene A. Friedman as
Vice President, General Counsel and Secretary.
"We are very pleased to add such a talented and experienced
executive to our senior management team...
|
|
MAP Pharmaceuticals Appoints Bernard J. Kelley to Board of Directors
Jun 26, 2007
|
4.9 KB |
|
| |
Mountain View, CA June 26, 2007 /PRNewswire - MAP Pharmaceuticals,
Inc. today announced the appointment of Bernard J. Kelley to the
company's Board of Directors.
Mr. Kelley retired from Merck and Co. Inc. in 2003, after more than
35 years of service to the company. Most recently, Mr....
|
|
MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting
Jun 22, 2007
|
4.5 KB |
|
| |
Mountain View, CA June 22, 2007 /PRNewswire - MAP Pharmaceuticals,
Inc. today announced that it will present Phase 2 data from its
Unit Dose Budesonide (UDB) pediatric asthma therapy clinical program
at the World Asthma Meeting at the Lütfi Kirdar Convention
and Exhibition Center ...
|
|
MAP Pharmaceuticals, Inc. Files Registration Statement for Proposed Initial Public Offering
Jun 18, 2007
|
4.6 KB |
|
| |
Mountain View, CA June 18, 2007 /PRNewswire - MAP Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and ...
|
|
MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the American Headache Society Meeting
Jun 5, 2007
|
6.8 KB |
|
| |
Mountain View, CA June 5, 2007/PRNewswire - MAP Pharmaceuticals, Inc. today announced that it will present Phase 2 data from its MAP0004 migraine therapy clinical program at the 49th Annual American Headache Society Meeting at the Hyatt Regency Chicago in Chicago, Illinois. The poster presentation, which was accepted as a late-b...
|
|
MAP Pharmaceuticals to Present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
Apr 10, 2007
|
4.0 KB |
|
| |
MOUNTAIN VIEW, Calif., April 10 /PRNewswire/ -- MAP Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on developing novel treatments for respiratory and CNS diseases, today announced that it will present a company update at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference in New ...
|
|
MAP Pharmaceuticals Closes $50 Million Financing
Mar 27, 2007
|
5.9 KB |
|
| |
Mountain View, CA, March 27, 2007 /PRNewswire/ -- MAP Pharmaceuticals,
Inc., a privately-held biopharmaceutical company focused on developing
novel treatments for respiratory and CNS diseases, today announced
the closing of its Series D equity financing in the amount of $50
million. T...
|
|
MAP Pharmaceuticals to Present at the Cowen & Company 27th Annual Health Care Conference
Mar 9, 2007
|
4.2 KB |
|
| |
MOUNTAIN VIEW, Calif., March 9 /PRNewswire/ -- MAP Pharmaceuticals,
Inc., a privately-held biopharmaceutical company focused on developing
novel treatments for respiratory and CNS diseases, today announced
that it will present a company update at the Cowen & Company
27th Annual He...
|
|
|
